Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Lonza announced its membership in the International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS). Through this consortium, Lonza will collaborate with other industry leaders to advance the research and development of inhalation...
read more
Lonza announced new investments in GMP laboratories and mid-scale manufacturing assets at its API manufacturing center in Nansha, China. The investments, totaling over $22 million, will allow Lonza to provide a smoother transition from small-scale to...
read more
Lonza expanded the range of particle engineering services offered by its Monteggio (CH) site through the introduction of X-ray powder diffraction (XRPD).
read more
Lonza, a CDMO partner to the biopharma industry, announced the extension of its collaboration with a major biopharmaceutical partner for the commercial-scale manufacture of monoclonal antibodies, under a long-term agreement. At scale, and following ...
read more
Tuesday, October 27, 2020
Lonza announced a $93m investment in its CHI Division, a dosage form delivery partner to the biopharma and health nutrition industry.
read more
Wednesday, December 02, 2020
Lonza has announced additional investments in its oral drug product development and manufacturing capabilities at its Tampa, Florida site.
read more
Thursday, December 10, 2020
Lonza has announced an investment to expand its particle engineering and drug product capabilities at its Oregon site.
read more
Lonza announced the start of expansion to its bioconjugation facility in Visp, Switzerland together with the successful commercial approval of a third ADC produced at the site.
read more
Lonza announced the completion of a laboratory expansion at its active pharmaceutical ingredients (API) manufacturing site at Nansha, China. The expansion focused on extending the capabilities and capacity of development laboratories and kilogram-...
read more
Lonza and Integral Molecular announced a strategy to offer complementary expertise to their respective customers to better assess the risks of off-target binding of biologic drug candidates.
read more
Lonza has enhanced its offering for customers in the early phases of their clinical trials by adding a dedicated Early Phase Clinical Manufacturing facility at its Small Molecules site in Bend, Oregon.
read more
Lonza announced it has completed the acquisition of Capsugel from KKR for $5.5 billion in cash, including refinancing of existing Capsugel debt of approximately $2 billion.
read more
Monday, February 03, 2020
Lonza announced a clinical manufacturing agreement with Rocket Pharmaceuticals, a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders.
read more
ValenzaBio, a biopharmaceutical company developing monoclonal antibody therapeutics for autoimmune and inflammatory indications, and Lonza announced that the companies have a manufacturing agreement in place.
read more
Thursday, September 08, 2022
Lonza agrees to cooperate with Touchlight to aid in genetic medicine advancement. Through this collaboration, Lonza will have the ability to integrate an additional,
read more